Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
08:00am, Wednesday, 03'rd Apr 2024
Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039 Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039
-- Subgroup Analyses from REDUCE-IT ® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (G
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
10:31am, Friday, 01'st Mar 2024
Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.
Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript
10:18am, Thursday, 29'th Feb 2024
Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:00am, Thursday, 29'th Feb 2024
-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 -- -- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
08:00am, Thursday, 15'th Feb 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, an
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
06:46am, Thursday, 15'th Feb 2024
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
Amarin Chairman & CEO Issue Letter to Shareholders
07:30am, Monday, 22'nd Jan 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Chairman of the Board, Odysseas Kostas, M.D., and Presi
Amarin: Sarissa Is Giving Me Hope Again
03:06am, Monday, 15'th Jan 2024
Sarissa Capital is successfully turning around Amarin, giving it new life and potential for success. Amarin's REDUCE-IT trial proved the cardiovascular benefits of its purified EPA product, Vascepa, l
Are Medical Stocks Lagging Amarin (AMRN) This Year?
11:19am, Friday, 12'th Jan 2024
Here is how Amarin (AMRN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
11:20am, Thursday, 11'th Jan 2024
Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million.
Why Amarin Stock Skyrocketed Today
07:02pm, Wednesday, 10'th Jan 2024
Amarin announced better-than-expected fourth-quarter results on Wednesday. The biopharmaceuticals company also announced a $50 million share repurchase program and guidance on capital allocation for 2
Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
06:40pm, Wednesday, 10'th Jan 2024
Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
Amarin stock soars on preliminary 4Q revenue guidance, share buyback plan
11:33am, Wednesday, 10'th Jan 2024
Amarin Corporation rose by more than a quarter on Wednesday after the drugmaker reported preliminary fourth-quarter revenues well ahead of analysts' expectations. In a business update ahead of its pre
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Monday, 11'th Dec 2023
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amar
